8 March 2016 - Cost regulators for the NHS in England and Wales are leaning towards a ‘no’ on the use of AbbVie’s Humira to treat the rare inflammatory skin disease hidradenitis suppurativa.

For more details, go to: http://www.pharmatimes.com/Article/16-03-08/NICE_to_reject_Humira_for_inflammatory_skin_disease.aspx